This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
Project oriented multidisciplinary
It has grown to reach a revenue of over US$ 650 million in 2013 with a growth of ~30% CAGR over the last 5 years. Intas has its extensive presence in over 40 countries worldwide with robust sales, marketing and distribution infrastructure in highly regulated markets like North America, Europe, Latin America, South Africa, Australia & New Zealand.
In India only Intas has state-of-art EU-GMP approved microbial manufacturing site. Under co-development relationship, Intas's first biosimilar has received positive review from CHMP (formal MA to be received within 2013). Second biosimilar has completed Phase I in Canada and further clinical development for EU, US and Canada market.
Intas believes in creating strong pipeline and thus adhering it's strategy, Intas has gearing up for clinical development of two more biosimilars for regulated market like US and EU.
Development & manufacturing Technologies available with Intas:
Products launched in domestic and semi-regulated markets:
? EPO a
? INF Alfa-2b
Additionally 9 biosimilars covering therapy segments of RA, fertility, non-cell small cancer, colon cancer, AMD are at various stages of development.